Emerging Evidence and Research Findings
Recent studies suggest GLP-1 drugs, including and Wegovy, may lower the risk of dementia, especially in individuals with type 2 diabetes. These findings are based on comprehensive analyses of existing clinical trials and health records.
One study found a 33% reduction in dementia risk for GLP-1 drug users, while another identified a 43% reduction with SGLT2 inhibitors. However, the latter's effect on dementia risk was not consistently observed across all studies.
Calls for Further Research and Clinical Trials
Despite the promising data, experts emphasize the need for more research to understand the mechanisms behind GLP-1 drugs' potential protective effects against dementia and to confirm these initial findings.
has initiated large-scale phase III trials to test semaglutide for early Alzheimer's disease, aiming to provide more definitive answers on its efficacy in dementia prevention.